BioMarin Pharmaceuticals Inc vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 7 of 9 compared factors.
Size & Scale
| BMRN | LLY | |
|---|---|---|
| Market Cap | $12.60 billion | $1.03 trillion |
| Revenue (TTM) | $3.41 billion | $79.67 billion |
| Net Income (TTM) | $72.97 million | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| BMRN | LLY | |
|---|---|---|
| P/E Ratio | 172.81 | 38.69 |
| Price / Book | 1.99 | 30.32 |
| Price / Sales | 3.70 | 12.89 |
BMRN leads on 2 of 3 valuation factors.
Profitability
| BMRN | LLY | |
|---|---|---|
| Net Margin | 2.14% | 33.53% |
| Return on Equity | 1.15% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| BMRN | LLY | |
|---|---|---|
| Dividend Yield | — | 0.60% |
| Payout Ratio | — | 23.23 |
BMRN and LLY split the dividend factors evenly.
Risk & Sentiment
| BMRN | LLY | |
|---|---|---|
| Short Interest | 4.98% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: BMRN overview, BMRN financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.